This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bonvalot, S. Articles by Le Cesne, A. Search for Related Content PubMed PubMed Citation Articles by Bonvalot, S. Articles by Le Cesne, A.

Impact of Surgery on Advanced Gastrointestinal Stromal Tumors (GIST) in the Imatinib Era

¹ Department of Surgery, Institut Gustave Roussy, 94805 Villejuif, France
² Radiotherapy, Institut Gustave Roussy, Villejuif, France
³ Radiology, Institut Gustave Roussy, Villejuif, France
⁴ Pathology, Institut Gustave Roussy, Villejuif, France
⁵ Medical Oncology, Institut Gustave Roussy, Villejuif, France

Correspondence: Address correspondence and reprint requests to: Sylvie Bonvalot; E-mail: bonvalot{at}igr.fr

Background: The role for surgery in patients with "unresectable" gastrointestinal stromal tumors (GIST) treated with imatinib is still not defined. The objective of this retrospective study was to evaluate the feasibility and benefit of this secondary surgery.

Methods: Progression-free survival (PFS) in a group of patients who underwent secondary surgery was compared to that of patients treated exclusively with imatinib.

Results: Of 180 patients with unresectable GIST treated with Imatinib, 22 (12%) underwent secondary surgery, following which one patient achieved a complete radiological response, 19 achieved a partial response (PR), in one patient the disease was stable, and in one patient there was reactivation of local occlusive disease after an initial PR. No patient with overall progression was to undergo surgery. At the beginning of imatinib therapy, five patients with metastases underwent emergency surgery [hemorrhage (n = 3) due to rupture of large necrotic masses], which ultimately resulted in three of the five patients dying postoperatively. A macroscopically complete resection was achieved in all primary tumors (5/5) and in ten of the 17 metastases. Pathological analysis revealed two complete response (CR) and 17 PR, and no treatment effect was evidenced in three patients. Two-year overall survival after surgery was 62%. The median PFS calculated from the initiation of imatinib therapy was 18.7 months for all operated patients and 23.4 months after planned surgery.

Conclusion: Primary tumors that become amenable to surgery with prior imatinib therapy, evolving necrosis and localized progression (to avoid life-threatening complications) could benefit from this secondary surgery. For the majority of other residual lesions, the potential benefit of secondary surgery should be evaluated in randomized studies in the future since PFS is similar to that reported among non-operated patients.

Key Words: Gastrointestinal stromal tumor • Surgery • Imatinib • Gleevec

This article has been cited by other articles:

				A. Artinyan, J. Kim, P. Soriano, W. Chow, S. Bhatia, and J. D.I. Ellenhorn Metastatic Gastrointestinal Stromal Tumors in the Era of Imatinib: Improved Survival and Elimination of Socioeconomic Survival Disparities Cancer Epidemiol. Biomarkers Prev., August 1, 2008; 17(8): 2194 - 2201. [Abstract] [Full Text] [PDF]

				C. P. Raut and R. P. DeMatteo Prognostic Factors for Primary GIST: Prime Time for Personalized Therapy? Ann. Surg. Oncol., January 1, 2008; 15(1): 4 - 6. [Full Text] [PDF]

				S. S. Yoon and K. K. Tanabe Should Surgical Resection Be Combined with Imatinib Therapy for Locally Advanced or Metastatic Gastrointestinal Stromal Tumors? Ann. Surg. Oncol., June 1, 2007; 14(6): 1784 - 1786. [Full Text] [PDF]